Naveruclif (Paclitaxel)

Paclitaxel, the active ingredient in Naveruclif, is a Taxane presented as an injectable formulation for intravenous use. It is employed to treat a range of solid tumours, including breast, lung and ovarian cancers, in adult patients, acting by disrupting cell division.

GNH USA supplies Naveruclif as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, adhering to EU GMP standards and providing reliable global distribution. The company ensures product integrity through rigorous quality control and temperature‑controlled logistics.

Paclitaxel is used in the management of solid tumours and certain malignancies, targeting rapidly dividing cancer cells.

- Breast cancer: administered in adjuvant or metastatic settings to inhibit tumour growth. - Non‑small cell lung cancer: used as first‑line or subsequent therapy for advanced disease. - Ovarian cancer: given in combination regimens to improve response rates in recurrent disease. - AIDS‑related Kaposi sarcoma: employed to control lesion progression in immunocompromised patients.

Paclitaxel may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Alopecia: hair loss that may be temporary. - Peripheral neuropathy: tingling or numbness in extremities. - Nausea and vomiting: gastrointestinal upset common during infusion. - Fatigue: generalized tiredness during treatment. - Myalgia: muscle aches and pains.

Serious or Rare Side Effects: - Hypersensitivity reactions: severe allergic responses requiring emergency care. - Cardiac arrhythmias: irregular heart rhythms observed during infusion. - Pulmonary toxicity: rare lung inflammation that can impair breathing. - Severe neutropenia with fever: life‑threatening infection risk. - Thromboembolic events: blood clots in veins or arteries.

Prior to initiating therapy, clinicians should assess patient suitability and monitor for potential complications.

- Monitor blood counts: perform regular CBC to detect neutropenia. - Assess for hypersensitivity: pre‑medicate with steroids and antihistamines as recommended. - Evaluate cardiac function: monitor ECG in patients with known heart disease. - Adjust for hepatic impairment: consider dose modification in severe liver dysfunction. - Pregnancy and lactation: avoid use unless benefits outweigh risks; discuss with specialist. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Paclitaxel interacts with several drug classes that can alter its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP2C8 inhibitors (e.g., gemfibrozil): may increase paclitaxel exposure and toxicity. - Concurrent use with other myelosuppressive agents: can exacerbate bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin): may reduce plasma concentrations, lowering effectiveness. - Neurotoxic drugs (e.g., vincristine): additive peripheral neuropathy risk. - Anticoagulants (e.g., warfarin): monitor coagulation parameters as paclitaxel may affect platelet function.